Law360, New York (February 13, 2007, 12:00 AM ET) -- Sanofi-Aventis will appeal a district court's ruling that its patent for anti-clotting drug Lovenox is unenforceable, Sanofi-Aventis' chief executive said Tuesday.
Sanofi-Aventis' patent infringement lawsuit against generic drug makers Amphastar Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc. was dismissed on Feb. 9. U.S. District Court Judge Mariana R. Pfaelzer ruled that Sanofi-Aventis was deceptive when it applied for its patent of the drug.
“We will strongly defend this patent and we will appeal,” Sanofi-Aventis Chief Executive Officer Gerard Le Fur said at an analysts’ meeting Tuesday....
Sanofi-Aventis To Appeal Lovenox Verdict
To view the full article, take a free trial now.
